Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The investigators design a multicenter randomized controlled trial to prove that RIF plus
ATRA is possibly superior to ATO plus ATRA as consolidation and maintenance treatment for the
patients with non-high-risk APL.
Phase:
Phase 3
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University